Nutra merchant accounts: what high-risk acquirers actually require

Nutra high-risk merchant account requirements come down to four files an acquirer underwrites, not one: substantiation for every product claim, a documented chargeback and refund record, billing terms that survive a consumer-protection review, and a corporate entity the acquirer is licensed and willing to contract with. Weak evidence in any one of them is what refusals are actually made of.

Scope of this article. The claims and billing analysis below works through the United States framework — the FTC Act and FDA labelling law — because most card-not-present supplement volume is sold into the US and because it is the regime an underwriter’s risk questionnaire is written against. The equivalent instruments in the EU, the UK and Singapore differ materially and are set out in the comparison near the end. If you sell into several of these markets, each set of rules applies to the traffic aimed at it.

What an acquirer is actually underwriting

A high-risk acquirer is not deciding whether it likes your product. It is pricing three exposures, and every document it asks for maps to one of them.

Regulatory exposure. If a regulator moves against your marketing, the merchant may stop trading overnight while refund liability stays with the acquirer. That is why the claims and labelling review comes before the financial review, and why an underwriter who finds one disease claim on one page will often decline before reading your processing statements.

Dispute exposure. Nutra generates disputes structurally: recurring billing, delivery lag, and a subjective product. The acquirer holds the loss if you cannot fund refunds, so it is sizing a reserve.

Counterparty exposure. The merchant of record must be an entity the acquirer can contract with under its own licence, verify beneficially, and pursue. This is where offshore shells fail — not on tax, on enforceability.

Every requirement below is a sub-question of one of those three. For the AML side of the same file — bank and EMI accounts rather than card acquiring — see why banks reject high-risk business account applications.

The claims file: why product marketing decides approval

The substantiation standard underwriters test against

US advertising claims about health benefits must be substantiated before dissemination. FTC staff guidance states the requirement plainly: advertisers must have “adequate substantiation for all objective product claims conveyed, expressly or by implication,” and claims about health benefits or safety “require substantiation in the form of competent and reliable scientific evidence.” The same guidance says that as a general matter this “will need to be in the form of randomized, controlled human clinical testing,” and that “numerous flawed and inadequate studies are unlikely to add up to competent and reliable scientific evidence”.

Two consequences matter commercially. Ingredient studies are not product studies — an underwriter will ask whether the trial used your formulation at your dose. And “advertising” is broad: the same guidance applies these principles to packaging and labelling, brochures, websites, social media and influencer marketing, press releases and claims made indirectly through practitioners.

Structure/function versus disease claims

US labelling law draws a bright line the FTC does not. Under 21 CFR 101.93, a supplement may bear statements describing the role of a nutrient in affecting the structure or function of the body, provided the marketer:

• notifies FDA’s Office of Dietary Supplement Programs no later than 30 days after first marketing the product bearing the statement, certifying it has substantiation that the statement is truthful and not misleading (§ 101.93(a));
• carries the disclaimer verbatim — “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” (§ 101.93(c)(1));
• places that disclaimer adjacent to the statement or linked by symbol, in boldface, in type no smaller than one-sixteenth inch (§§ 101.93(d)–(e)).

Cross the line into disease territory and § 101.93(f) applies: the product is regulated as a drug. Note the division of labour the FTC describes — FDA has primary responsibility for claims in labelling, the FTC for claims in advertising — but the FTC is explicit that this liaison arrangement “doesn’t limit the FTC’s jurisdiction or prohibit the agency from taking action against deceptive labeling claims.”

Testimonials, before-and-afters and affiliate landers

Most nutra files fail here, because the merchant did not write the page that sank it. The FTC Endorsement Guides provide that an advertiser must have substantiation for claims conveyed through endorsements “in the same manner the advertiser would be required to do if it had made the representation directly,” and that “[c]onsumer endorsements themselves are not competent and reliable scientific evidence”. Where an endorser’s experience is not representative, the ad must clearly and conspicuously disclose the generally expected performance. Separately, 16 CFR § 255.5 requires clear and conspicuous disclosure of material connections — including free or discounted product, the possibility of payment, or the chance of winning a prize.

Underwriters increasingly ask to see the affiliate agreement, the creative-approval process and the takedown log. If you run paid affiliate traffic, the compliance controls over that channel are part of the merchant file, and our affiliate and performance-marketing account opening work addresses the same problem from the network side.

Chargeback monitoring and how merchants exit it

Both major card schemes operate acquirer- and merchant-level monitoring programmes that measure disputes and fraud as a ratio of transactions. Once a merchant crosses the scheme’s published threshold, it is identified to the acquirer, placed into a remediation period, and becomes subject to escalating fees and, ultimately, to the acquirer’s decision to exit the relationship. The programmes are administered through the schemes’ operating rules — Visa publishes its rules in the Visa Core Rules and Visa Product and Service Rules — and the thresholds, measurement windows and fee schedules have been revised repeatedly. We deliberately do not quote a figure here. Ask your acquirer to confirm, in writing, the current programme, the ratio that applies to you and the count floor beneath which you are not measured, and get it re-confirmed at renewal.

What is stable is the mechanism that generates the disputes, and that is legal rather than commercial:

• Delivery is a billing error. Under Regulation Z, 12 CFR § 1026.13(a)(3), a charge for property or services “not accepted by the consumer or the consumer’s designee, or not delivered to the consumer or the consumer’s designee as agreed” is a billing error. Slow fulfilment converts directly into disputes.
• The clock is long. A consumer’s billing error notice is timely if received no later than 60 days after the creditor transmitted the first periodic statement showing the item (§ 1026.13(b)(1)). Disputes therefore arrive months after the sale, which is why a merchant’s ratio deteriorates after a scaling campaign, not during it.
• Shipping timing is itself a rule. Under the FTC’s Mail, Internet, or Telephone Order Merchandise Rule, 16 CFR § 435.2(a)(1), a seller must have a reasonable basis to expect shipment within the time clearly and conspicuously stated, or within 30 days if no time is stated. Absent records of systems assuring shipment, the rule creates a rebuttable presumption against the seller.

Acquirers know this. A file that shows a documented refund policy, a customer-service SLA, a chargeback-alert subscription and a fulfilment partner with real dispatch data is underwritten differently from one that shows a ratio and an assurance.

Trials, rebills and the practices that get you terminated

Negative-option billing is the single largest source of nutra terminations. In the US the governing statute is ROSCA. Section 8403 makes it unlawful to charge a consumer for goods or services sold online through a negative option feature unless the seller: (1) clearly and conspicuously discloses all material terms before obtaining billing information; (2) obtains express informed consent before charging; and (3) provides “simple mechanisms for a consumer to stop recurring charges”.

The regulatory layer above ROSCA is in flux and you should know which way. The FTC’s 2024 amended Negative Option Rule — the “click-to-cancel” rule — was vacated by the Eighth Circuit in Custom Communications, Inc. v. FTC in July 2025 on procedural grounds. In its Advance Notice of Proposed Rulemaking announced on 11 March 2026, the Commission itself refers to “the vacated 2024 Rule” and asks whether it should retain the current Prenotification Negative Option Rule, adopt provisions of the vacated rule, or pursue alternatives. Practical reading: the federal rulemaking is unsettled, ROSCA and FTC Act Section 5 enforcement is not, and a number of US states impose their own subscription-cancellation requirements regardless.

What an acquirer will look for in your funnel, in practice: the trial price, the post-trial price, the billing interval and the cancellation route disclosed on the same screen as the payment field rather than in linked terms; an affirmative tick or equivalent that is not pre-checked; a cancellation path that does not require a phone call at hours you do not staff; a pre-billing reminder email; and descriptor text that matches the brand the customer bought from. Merchants terminated for chargebacks have usually been terminated for one of these first.

Which corporate structure and jurisdiction gets underwritten

There is no jurisdiction that makes a nutra merchant bankable. There are jurisdictions that make it contractable, and that is the real constraint.

Acquirers are licensed for defined territories and will generally onboard a merchant of record established where they are permitted to acquire, with the settlement account in the same name. A Seychelles or BVI company with a payment institution account in a third country is a structure most nutra acquirers decline before underwriting begins — not for tax reasons but because the merchant agreement, the reserve and the indemnity have to be enforceable. In practice that pushes European-facing nutra towards an EU or UK operating entity, and US-facing volume towards a US entity with a US processing history.

Regulatory responsibility follows the entity as well. In the EU, Article 8(1) of Regulation (EU) No 1169/2011 puts responsibility for food information on “the operator under whose name or business name the food is marketed or, if that operator is not established in the Union, the importer into the Union market.” Whichever company is named on your label is the company holding the compliance exposure — so the label entity, the merchant of record and the entity in the acquirer’s file should be the same one, or you should be able to explain in one sentence why they are not.

Choosing among those options is a formation question before it is a banking question. We handle both together: see company formation across our jurisdictions, in particular UK company formation and Cyprus company formation for EU- and UK-facing supplement sellers, and our payments and card-acquiring practice where the structure needs a licensed entity of its own.

The document pack, in the order underwriting reads it

• Products and claims. SKU list, full label artwork, ingredient and certificate-of-analysis documentation, manufacturing/supplier agreements, and the substantiation dossier tied claim-by-claim to each product.
• Marketing. Live URLs for every funnel, all creative variants, the affiliate agreement, the creative-approval and takedown process, and the list of markets targeted.
• Billing. Checkout screenshots, terms of sale, refund policy, cancellation flow, pre-billing reminder templates and the billing descriptor.
• Performance. Twelve months of processing statements, chargeback and refund ratios by month with the reason-code breakdown, and evidence of any remediation already carried out.
• Fulfilment. 3PL or fulfilment contract, dispatch times, tracking coverage rate, and customer-support hours and channels.
• Corporate. Incorporation documents, ownership chart to beneficial owners, UBO identification, source-of-funds evidence, and the settlement account details in the merchant’s own name.

We assemble exactly this pack, in this order, as part of nutra and supplements account opening, and file it with acquirers and EMIs that have a genuine appetite for the vertical rather than a published policy that says they might. The same approach applies across our high-risk account opening work.

How the rules differ outside the United States

If you sell into Europe, the UK or Asia, the substantiation question is answered by a different instrument — and in the EU it is answered by a closed list rather than by evidence you hold.

Two EU points catch US-built funnels immediately. Article 7(3) of Regulation (EU) No 1169/2011 provides that food information “shall not attribute to any food the property of preventing, treating or curing a human disease, nor refer to such properties,” and Article 7(4) extends that to advertising and presentation — the same prohibition appears for supplements specifically in Article 6(2) of Directive 2002/46/EC. And under Article 10 of that Directive, Member States may require notification to the competent national authority, with a model label, before a supplement is placed on their market — so market entry is a country-by-country exercise, not an EU-wide one.

On billing, the EU equivalent of ROSCA sits in the Consumer Rights Directive: Article 8(2) of Directive 2011/83/EU requires the order button to be labelled “order with obligation to pay” or an equivalent unambiguous formulation, and provides that if the trader has not complied, “the consumer shall not be bound by the contract or order” — with a 14-day withdrawal right under Article 9(1). In the UK, the dedicated subscription-contracts regime in Part 4, Chapter 2 of the Digital Markets, Competition and Consumers Act 2024 is not yet in force: the Government’s response to its implementation consultation states that it will legislate when parliamentary time allows and “anticipates that the regime will commence in spring 2027”. Until then the 2013 Consumer Contracts Regulations continue to govern.

This article is general information about regulatory and underwriting practice, current as at the date of publication, and is not legal advice. Card-scheme thresholds, acquirer policies and consumer-protection rules change; confirm the position for your products, markets and processing profile before acting. To discuss a specific file, start with our nutra and supplements account opening service.